DiscoverLung Cancer ConsideredIASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy
IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

Update: 2025-09-26
Share

Description

This episode of Lung Cancer Considered reviews new and upcoming approvals for subcutaneous immune checkpoint inhibitors. Join host Dr. Narjust Florez and guests, Dr. Cheryl Ho and Dr. Maria Velez Velez, for a discussion of the formulation and its place in the management of patients with lung cancer.

Guests:

Cheryl Ho, MD, FRCPC
Thoracic Oncologist, BC Cancer
Clinical Associate Professor and Fellowship Program Director
University of British Columbia

Maria Velez Velez, MD, MS
Clinical Instructor, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy

IASLC